Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor | |
Wang, Wenxian2; Wang, Qian3; Xu, Chunwei4,5; Li, Ziming6; Song, Zhengbo2; Zhang, Yongchang7; Cai, Xiuyu8; Zhang, Shirong9; Lian, Bin10; Li, Wen11 | |
刊名 | THORACIC CANCER |
2022-10-21 | |
关键词 | checkpoint inhibitor pneumonitis Chinese experts consensus immune checkpoint inhibitor-related adverse effects |
ISSN号 | 1759-7706 |
DOI | 10.1111/1759-7714.14693 |
通讯作者 | Si, Lu(silu15_silu@126.com) ; Fang, Wenfeng(fangwf@sysucc.org.cn) ; Song, Yong(yong.song@nju.edu.cn) |
英文摘要 | Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP. |
WOS关键词 | CELL LUNG-CANCER ; ADVERSE EVENTS ; PD-1/PD-L1 INHIBITORS ; SAFETY ; EFFICACY ; IMMUNOTHERAPY ; ANTI-PD-1 ; MELANOMA ; NSCLC ; CHEMOTHERAPY |
WOS研究方向 | Oncology ; Respiratory System |
语种 | 英语 |
出版者 | WILEY |
WOS记录号 | WOS:000877840500001 |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130206] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Si, Lu; Fang, Wenfeng; Song, Yong |
作者单位 | 1.Collaborat Innovat Ctr Jiangsu Prov Canc Prevent, Nanjing, Peoples R China 2.Chinese Acad Sci Univ Canc Hosp, Dept Chemotherapy, Zhejiang Canc Hosp, Hangzhou, Peoples R China 3.Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Affiliated Hosp, Nanjing, Peoples R China 4.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou, Peoples R China 5.Nanjing Univ, Affiliated Jinling Hosp, Dept Resp Med, Med Sch, Nanjing 210002, Jiangsu, Peoples R China 6.Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai, Peoples R China 7.Cent South Univ, Dept Med Oncol,Xiangya Sch Med, Lung Canc & Gastrointestinal Unit, Hunan Canc Hosp,Affiliated Canc Hosp, Changsha, Peoples R China 8.Sun Yet Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept VIP Inpatient, State Key Lab Oncol South China, Guangzhou, Peoples R China 9.Zhejiang Univ, Translat Med Res Ctr, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Affiliated Hangzhou Peoples Hosp 1,Canc Ctr, Hangzhou, Peoples R China 10.Peking Univ Canc Hosp & Inst, Dept Melanoma & Sarcoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China |
推荐引用方式 GB/T 7714 | Wang, Wenxian,Wang, Qian,Xu, Chunwei,et al. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor[J]. THORACIC CANCER,2022. |
APA | Wang, Wenxian.,Wang, Qian.,Xu, Chunwei.,Li, Ziming.,Song, Zhengbo.,...&Song, Yong.(2022).Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.THORACIC CANCER. |
MLA | Wang, Wenxian,et al."Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor".THORACIC CANCER (2022). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论